MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ
325.30
+2.90
+0.90%
After Hours: 325.30 0 0.00% 16:10 07/24 EDT
OPEN
322.29
PREV CLOSE
322.40
HIGH
327.51
LOW
314.62
VOLUME
282.58K
TURNOVER
--
52 WEEK HIGH
366.52
52 WEEK LOW
37.19
MARKET CAP
9.07B
P/E (TTM)
-24.3353
1D
5D
1M
3M
1Y
5Y
1D
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth
Seeking Alpha · 2d ago
Praxis Precision Medicines (PRAX) Has a New Rating from Goldman Sachs
TipRanks · 3d ago
ClearBridge Small-Cap Growth Strategy adds new positions, exits others
Seeking Alpha · 4d ago
Weekly Report: what happened at PRAX last week (0713-0717)?
Weekly Report · 4d ago
Praxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach
Simply Wall St · 4d ago
Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?
Simply Wall St · 07/16 03:46
Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)
TipRanks · 07/13 16:10
Analysts Are Bullish on Top Healthcare Stocks: Praxis Precision Medicines (PRAX), Sino Biopharmaceutical (SBMFF)
TipRanks · 07/13 12:40
More
About PRAX
Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others.

Webull offers Praxis Precision Medicines Inc stock information, including NASDAQ: PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.